Moderna Inc (MRNA)

[axelvento]

"stay tuned" The Phase 2 trial is fully enrolled and primary data are expected in the fourth quarter of 2022..." We are in the 4th quarter of '22.

cancer vaccine mRNA-4157.....Under the agreement, originally established in 2016 and amended in 2018, Merck will pay Moderna $250 million to exercise its option for personalized cancer vaccines including mRNA-4157/V940 and will collaborate on development and commercialization.The payment willbe expensed by Merck in the third quarter of 2022 and included in its non-GAAP results. Merck and Moderna will share costs and any profits equally under this worldwide collaboration.